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Abstract: Robust humoral and cellular immunity are critical for survival in humans during an
ebolavirus infection. However, the interplay between these two arms of immunity is poorly
understood. To address this, we examined residual immune responses in survivors of the Sudan virus
(SUDV) outbreak in Gulu, Uganda (2000–2001). Cytokine and chemokine expression levels in SUDV
stimulated whole blood cultures were assessed by multiplex ELISA and flow cytometry. Antibody and
corresponding neutralization titers were also determined. Flow cytometry and multiplex ELISA
results demonstrated significantly higher levels of cytokine and chemokine responses in survivors
with serological neutralizing activity. This correspondence was not detected in survivors with
serum reactivity to SUDV but without neutralization activity. This previously undefined relationship
between memory CD4 T cell responses and serological neutralizing capacity in SUDV survivors is
key for understanding long lasting immunity in survivors of filovirus infections.
Keywords: Ebola survivors; memory immunity; neutralizing antibodies; cellular immunity
1. Introduction
Ebolavirus is a member of the Filoviridae family and the cause of viral hemorrhagic fever disease [1].
Studies that examined the pathogenesis of Ebolavirus infection in humans indicate that recovery is
largely dependent upon, and associated with, the development of both cell-mediated and humoral
Viruses 2016, 8, 133; doi:10.3390/v8050133 www.mdpi.com/journal/viruses
Viruses 2016, 8, 133 2 of 12
immune responses [2–5]. Ebolavirus infection triggers the release of cytokines and chemokines,
including interleukin (IL)-1β, IL-6, IL-8, IL-10, interferon (IFN)-γ, monocyte chemoattractant protein
(MCP)-1, and IFNγ-inducible protein (IP)-10 [6–8]. In addition, evidence from studies that examined
survivors and asymptomatic cases demonstrated the presence of significant levels of virus-specific
IgM and IgG associated with a temporary, early and strong inflammatory response [5,9,10].
Prior to the recent outbreak in West Africa [11,12], one of the largest known outbreaks of
ebolavirus, SUDV, occurred in Gulu, Uganda in 2000–2001, resulting in 425 cases and 224 fatalities [13].
The causative agent of this outbreak was named the Sudan virus (SUDV). Studies of the survivors
of this outbreak indicate that the composition of survivor memory immune responses includes
pro-inflammatory cytokine responses and antibody responses to SUDV antigens [14,15]. Further work
has also demonstrated that a persistent humoral memory immune response with neutralization
capacity was not present in all survivors of this cohort group and that a complete lack of memory
humoral immunity was also observed in many survivors [16]. However, previous experiments that
characterized SUDV survivor immune responses did not specifically measure antiviral memory T cell
responses and could not determine the provenance of the cytokines being measured [15]. To address
this, we obtained fresh whole blood samples from survivors of the Gulu SUDV outbreak, along
with uninfected control individuals, and performed whole blood stimulation with SUDV antigens.
The induced cytokine responses of memory T cells were studied by flow cytometry, coupled with
multiplex ELISA to measure secreted cytokines and chemokines in supernatants of stimulated samples.
Additionally, SUDV-specific IgG levels and SUDV-specific neutralization capacity were also assessed
in matched serum samples. The results demonstrated a previously undefined correspondence between
memory CD4 T cell responses and serological neutralizing capacity in SUDV survivors. Furthermore,
survivors with significant serological immunoreactivity to ebolavirus antigens, but lacking serological
neutralization capacity, failed to demonstrate this correspondence. As a result, this study reveals a
potential linkage between only the neutralizing arm of the humoral immune response and cellular
immunity in ebolavirus survivors.
2. Materials and Methods
2.1. Study Design
Subjects included confirmed survivors, according to patients PCR and ELISA results, from the
SUDV outbreak of 2000–2001 in Gulu district, Uganda [17], and healthy local community members
that were not infected. Study participants were not related.
2.2. Ethics Statement
The study was approved by the Helsinki committees of the Uganda Virus Research Institute in
Entebbe, Uganda (reference number GC/127/13/01/15), Soroka Hospital, Beer-sheva, Israel (protocol
number 0263-13-SOR) and the Ugandan National Council for Science and Technology (UNCST)
(registration number HS1332). Written informed consent as well as a personal health questionnaire
was completed for each subject.
2.3. Sample Collection
Whole blood samples were obtained by routine antecubital venipuncture. Samples were directly
aspirated into sterile vacutainers containing freeze-dried sodium heparin (final heparin concentration
14.3 units/mL, (Becton Dickinson, Franklin Lakes, NJ, USA). and kept at 4 ˝C until assayed. Assays
were initiated approximately 6 h after being collected and 2 h after the samples were processed.
2.4. Antigens and Stimulations
Stimulation assay antigen included irradiated, sucrose gradient purified, SUDV (Gulu isolate) [16].
A lectin from Phaseolus vulgaris Leucoagglutinin, PHA-L, (Sigma-Aldrich, Rehovot, Israel) was used as
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a positive control for cell stimulation. For ELISA assays, irradiated SUDV (Gulu isolate), recombinant
SUDV GP1-649, and total 293T cell lysate that expressed a given recombinant SUDV protein (NP, VP30,
VP35 and VP40) were used as the capture antigens. Construction of the recombinant SUDV viral gene
expression vectors and production of irradiated SUDV have been described previously [18].
2.5. Internal Control Sera
Internal human control sera for ELISA were previously described [16]. Positive controls for the
detection of SUDV GP1-649 included murine monoclonal antibody 3C10 that targets SUDV GP1-649 [19].
2.6. Specific IgG Detection Assays
The levels of circulating anti-SUDV and anti-SUDV recombinant viral protein antibodies were
determined by chemiluminescence ELISA, as previously described [15,16].
2.7. Normalization of Raw Data and Selection of Cut-off Values
Calculation of signal to noise (S/N) values for anti-SUDV recombinant proteins NP, VP30, VP35,
and VP40 specific IgG was performed as previously described [18]. Calculation of S/N values was
performed using the formula: (average result of control or test serum against cell lysate expressing the
recombinant viral protein/average result of control or test serum against cell lysate not expressing
the recombinant viral protein (mock antigen)). The cut-off value for IgG positive immune-reactivity
was determined with a control set of negative sera and ten-fold stratified cross-validation analysis [20].
For the purified SUDV, and SUDV GP1-649 protein, raw ELISA data were converted to percent positivity
(PP) of a high internal control antibody since we did not assay a mock antigen. Calculation of PP values,
as well as the cut-off value, was performed as previously described [21]. Normalization of cytokine
and chemokine expression levels in whole blood stimulation assays was performed by removing
the background (unstimulated expression) for each respective stimulated sample. Determination of
the cut-off value for positive cytokine stimulation was performed as follows: for each cytokine or
chemokine, the average background value (no stimulation) was determined using all tested samples.
Next, raw data for each stimulated sample was divided by the background value. Cut-off selection
was then set using the average + 2XSD of the uninfected control group. Low positive (+), medium
positive (++) and strong positive (+++) was determined as X < 2, 2 < X < 4, and 4 < X above the cut-off
value, respectively.
2.8. Plaque Reduction Neutralization Test
Plaque reduction neutralization assays (PRNT80) were performed as previously described [22].
Neutralization titers were determined to be the last dilution of serum that reduced the amount of
plaque by 80% compared with control wells. Plaque reduction neutralization assays were performed
in the BSL-4 lab of United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
(Fort Detrick, Frederick, MD, USA).
2.9. Whole Blood Stimulation from SUDV Survivors and Healthy Volunteers
Whole blood stimulation was performed as previously described [15,23] with minor modifications.
Freshly obtained, heparinized venous blood from SUDV survivors and healthy volunteers was
aliquoted into 12 ˆ 75 mm snap-cap polypropylene tubes under sterile conditions. Each blood
sample from both survivor and control subjects was diluted 1:4 in RPMI-1640 (Roswell Park Memorial
Institute medium) supplemented with 5% FCS (Fetal Calf Serum). SUDV antigen (10 µg/mL)
was added to individual aliquots (1.0 mL final vol) and the cultures were incubated at 37 ˝C in
a 5% CO2 humidified environment for 22 h. For the final four hours of incubation, whole blood
cultures were supplemented with brefeldin A (eBioscience, San Diego, CA, USA) to trap intracellular
cytokines. Following incubation, cells were pelleted and processed for flow cytometry analysis while
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culture supernatants were aspirated, transferred to new 1.5 mL tubes and frozen at ´70 ˝C until
further processing.
2.10. Cytokine and Chemokines Detection Using Q-Plex™ ELISA-Based Chemiluminescent Assay
Levels of human cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IL-23 IFNγ and
TNFα and chemokines GROα, Eotaxin, I-309, IP-10, MCP-1 and MCP-2 were detected using Q-Plex
technology (Quansys Biosciences, Logan, UT, USA) according to the manufacturer’s instructions.
Readouts were obtained with a Quansys Imager (Quansys Biosciences) and results analyzed using the
Q-View Software program (Quansys Biosciences). A human sL-Selectin Instant ELISA (eBioscience)
was also performed according to the manufacturer’s recommended protocol, with the exception that
culture supernatants were diluted 1:10, of which 50 µL was added to provide plates in duplicate.
2.11. Flow Cytometry Analysis
Following lysis of red blood cells, cells were washed in PBS and stained with Aqua live/dead
dye (Life Technologies, Carlsbad, CA, USA). Prior to surface staining, cells were incubated with 1%
mouse serum in flow staining buffer (eBioscience) to block nonspecific binding. Surface markers
were stained for CD4, CD8, CD45RO, CD62L and CD3. Following fixation in 4% paraformaldehyde
(BioLegend, San Diego, CA, USA), cells were permeabilized in 1ˆ perm/wash (eBioscience) and
incubated with antibodies against IFNγ and TNFα. Cells were stored in flow staining buffer at 4 ˝C
prior to acquisition on an LSR II (BD Biosciences, San Jose, CA, USA). Flow cytometry data was
analyzed in FlowJo (Tree Star, Ashland, OR, USA) and Excel (Microsoft, Redmond, WA, USA) and
graphed in GraphPad Prism (GraphPad Software Inc., LA Jolla, CA, USA).
2.12. Statistical Analysis
Statistical analyses were performed using GraphPad Prism software 6.01 (GraphPad Software, Inc.).
Correlation analysis was assessed by the Spearman nonparametric test. Differences in cytokine values
between study groups were assessed by analysis of variants (ANOVA) and Wilcoxon rank sum test;
p-values represent 2-sided p-values, and p-values < 0.05 were considered statistically significant.
3. Results
3.1. Cohorts and Blood Samples
Whole blood samples were obtained from 15 survivors of the SUDV outbreak in Gulu and five
from uninfected members of the Gulu community, which served as controls. Samples were collected
approximately 12 years post infection and all within 3 h of each other. All subjects were healthy and
reported a lack of autoimmune diseases, cancer and past hospitalizations, unrelated to ebolavirus
disease (EVD), suggesting a lack of confounding infections. Survivors reported uniform treatment
(supportive care only) and symptoms during and after the acute illness.
3.2. Humoral Immune Responses to SUDV Proteins and Neutralization Profiles
We assessed the profile of IgG immune-reactivity using a custom made ELISA previously
described [18]. Survivor serum samples were analyzed against SUDV recombinant proteins NP, VP30,
VP40, GP1-649, and irradiated purified whole virus antigen. The results presented in Figure 1A–E) and
Table 1 demonstrate that in the 15 SUDV survivors tested, 11 displayed positive antibody-reactivity to
NP, nine to GP1-649, and VP40, and four to VP30. Six survivors exhibited a positive antibody response
against the irradiated SUDV whole purified virus antigen. Serum from uninfected controls displayed
no reactivity to any of the viral antigens tested. A plaque reduction neutralization test (PRNT) was
performed to determine the neutralization capacity of survivor sera at various dilutions (Figure 1F and
Table 1). We defined neutralization as the ability of a given serum sample, regardless of dilution, to
neutralize 80% of SUDV plaque formation (PRNT80) relative to controls. The results demonstrate that
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of the 15 SUDV survivors tested, sera from 6 survivors displayed a PRNT80 capacity. The remaining
nine survivors and five uninfected controls were non-neutralizing by the applied definition.
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(PRNT80) results of SUDV survivors and non-infected controls. 
Serology 
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C4 − − − − − −
C5 − − − − − −
S1 ++ − + − − −
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Figure 1. Summary of serological immune-reactivity and plaque reduction neutralization tests
(PRNT80) of SUDV survivors and non-infected controls. (A–E) Serum samples from 15 SUDV
survivors and 6 non-infected controls were tested by ELISA against individual recombinant SUDV viral
proteins NP (A), VP30 (B), VP40 (C) and GP1-649 (D) as well as irradiated SUDV whole virus (E).
Individual cut-off values for each tested viral protein or irradiated whole antigen is presented
(dashed line). (F) Dilutions of serum samples (20, 40 and 80 fold) collected from SUDV survivors
and uninfected controls were assayed for their ability to neutralize live SUDV in vitro under BSL4
conditions. The cut off value for the PRNT80 assay is denoted by the dashed line. S/N = Signal to Noise.
PP = Positive percentage. S—SUDV survivor. C—Non-infected control. Percentage of neutralization is
expressed as: 100 ´ [100 ˆ (number of SUDV plaques obtained at given serum dilution/number of
control SUDV plaques)].
Table 1. Summary of serological immune-reactivity and plaque reduction neutralization tests (PRNT80)
results of SUDV survivors and non-infected controls.
Serology
NP VP40 VP30 GP1–649 1 SUDV PRNT80
C1 ´ ´ ´ ´ ´ ´
C2 ´ ´ ´ ´ ´ ´
C3 ´ ´ ´ ´ ´ ´
C4 ´ ´ ´ ´ ´ ´
C5 ´ ´ ´ ´ ´ ´
S1 ++ ´ + ´ ´ ´
S2 ´ + ´ ´ ´ ´
S3 ´ ´ ´ ´ ´ ´
S4 ´ ´ ´ ´ ´ ´
S5 ´ ´ ´ ´ ´ ´
S6 +++ ´ + ´ +++ ´
S7 + ´ + + ´ ´
S8 +++ + ´ +++ ´ ´
S9 ++ + ´ +++ +++ ´
S10 +++ +++ ´ +++ +++ +++
S11 +++ ++ ´ +++ ´ +
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Table 1. Cont.
Serology
NP VP40 VP30 GP1–649 1 SUDV PRNT80
S12 +++ +++ ´ +++ + +
S13 +++ +++ + +++ +++ +++
S14 +++ + ´ +++ +++ +++
S15 +++ +++ ´ +++ ´ ++
1 A purified recombinant protein containing the 649 amino terminal amino acids of SUDV GP without the
trans-membrane domain. S: Ebola survivors, C: non–infected controls. PRNT: plaque reduction neutralization
test ELISA: (´) = ď cut-off value. (+) = < 2ˆ cut off value, (++) = > 2ˆ cut off value and < 4ˆ cut off value,
(+++) = > 4ˆ cut off value. PRNT80: (+): neutralizes at 1:20 dilution, (++): neutralizes at 1:40 dilution, (+++):
neutralizes at greater than 1:80 dilution.
3.3. Flow Cytometry
Flow cytometry analysis of IL-4, TNFα and IFNγ cytokine levels was performed following cell
stimulation with SUDV inactivated whole antigen. Based on the humoral reactivity of serum samples
observed in both the ELISA and PRNT80 assays (Table 1), we chose to group the survivors into the
following categories for analytic purposes: those who have no immune-reactivity against SUDV
GP1-649 or inactivated SUDV and were PRNT80 negative (Ab´/Neut´); those who react against SUDV
GP1-649 and/or inactivated SUDV but were PRNT80 negative (Ab+/Neut´); and those who react
against SUDV antigens and also have a PRNT80 capacity against live SUDV in vitro (Ab+/Neut+)
(Table 1). Uninfected controls were also included and grouped separately.
Flow cytometry data showing IFNγ and TNFα expression by cells after stimulation with SUDV
antigen for all survivors and controls is presented in Figure 2A. All plots shown are gated hierarchically
as follows: lymphocytes (FSC-A vs. SSC-A), singlets (FSC-A vs. FSC-H), live cells (Aqua live/dead
negative), CD3+ (CD3 vs. SSC-A), and CD4+ CD8´ (Figure 2B). Resting values for each survivor or
control are included in each quadrant in parentheses (Figure 2A). Cells from uninfected control samples
did not express any IFNγ or TNFα in response to SUDV stimulation. One survivor in the SUDV
Ab´/Neut´ group had a diverse CD4 T cell response, comprised of IFNγ and TNFα-single positive as
well as double positive cytokine-producing cells (Figure 2A). All other Ab´/Neut´ and Ab+/Neut´
survivors demonstrated an absence of cytokine production in response to SUDV stimulation. In stark
contrast, survivors with PRNT80 serum capacity against SUDV in vitro all had multivariate cytokine
responses (Figure 2A). The extent of response varied from survivor to survivor but overall, IFNγ
and TNFα double-positive (DP) responses predominated. IFNγ single positive (SP), TNFα SP, and
DP frequencies in the Ab+/Neut+ were significantly higher than all other groups for each subset of
cytokine-producing cells (p < 0.05) (Figure 2C). Flow cytometry data of IL-4 cytokine levels following
cell stimulation with SUDV inactivated whole antigen showed no detectable signals in both survivors
and controls.
A correlation analysis between cytokine expression and neutralization activity (at 1:80 dilution)
demonstrated a significant correlation between the cytokine and neutralization responses (Table 2).
The correlation between neutralization and IFNγ, TNFα DP and TNFα SP cytokine responses was
slightly higher than for IFNγ SP responses (Table 2). Only two of the 15 survivors had apparent CD8 T
cell responses to SUDV (Supplemental Material Figure S1) consisting of IFNγ and TNFα expression.
Due to the rarity of these responses, we were unable to do further analysis.
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Figure 2. Flow cytometry results, gating strategy and analysis of whole blood from survivors and
non-infected controls following SUDV whole antigen stimulation. (A) Plots depict IFNγ and TNFα
cytokine responses in CD4 T cells following 22 h of stimulation with inactivated SUDV antigen, in
non-infected controls, SUDV survivors without antibodies response, SUDV survivors with antibodies
response and neutralization capability. Values in parentheses indicate the respective values for resting
cultures that did not receive antigen; (B) Gating strategy for plots shown in (A); (C) Grouped column
scatter plot showing the frequency of IFNγ single positive (SP), TNFα SP, or double positive (DP)
events among CD4 T cells. Survivors are grouped according to the presence of IgG antibodies to SUDV
antigen or GP1-649 and ability to neutralize live SUDV (Table 1). S: SUDV survivor; C: non-infected
control; SP: single positive; DP: double positive; *: p < 0.05 SUDV Neut+ vs. SUDV Ab+ no Neut;
#: p < 0.05 SUDV Neut+ vs. no SUDV Ab.
Table 2. Correlation analysis between neutralization (1:80 dilution) and cytokine and chemokine
secretion levels by multiplex ELISA and Flow cytometry following SUDV whole antigen stimulation in
SUDV survivors and non-infected controls.
Multiplex ELISA Flow
IL-2 IL-5 IFNγ TNFα GROα IP-10 - Eotaxin IFNγ TNFα TNFα + IFNγ
Spearman r 0.4672 0.0704 0.6892 0.2141 0.0778 0.6999 0.6860 0.2577 0.6714 0.7672 0.7561
p value (two side) 0. 378 0.7679 0.0011 0.3646 0.7442 0.0006 .0008 0.27 7 0.0012 <0.0001 0.0001
IL—Interleukin, IFN—Interferon, TNF—Tumor necrosis factors, IP—IFNγ-inducible protein, MCP—Monocyte
chemotactic protein. p values < 0.05 were considered statistically significant.
We also performed a memory subset analysis for survivors that had SUDV-specific CD4 T
cell cytokine responses, regardless of whether or n t they had SUDV-specific antibodies or serum
neutralization capacity. We used CD62L and CD45RO in this analysis to identify central mem ry T cells
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(TCM, CD45RO+ CD62L+), effector memory T cells (TEM, CD45RO+ CD62L´), terminally-differentiated
effector memory T cells (TEMRA (CD45RO´ CD62L´), and naïve T cells (CD45RO´, CD62L+).
Each cytokine-producing subset was overlaid upon the parent CD4 T cell population for reference.
Virtually all IFNγ SP and IFNγ, TNFα DP cells were in the TEM subset (Figure 3A) with two survivors
(upper right, lower left) that also had TEMRA cells. Only TNFα SP cells were found in the TCM subset
(Figure 3A). As CD62L can be cleaved from the cell surface upon T cell activation, we performed an
ELISA for soluble CD62L (sCD62L) in the supernatants of these cultures. We were unable to establish
a pattern of increased sCD62L in cultures that corresponded to cytokine production, which would
have indicated that CD62L had been cleaved due to T cell activation (Figure 3B). sCD62L levels were
variable regardless of stimulation or resting culture for all controls and survivors (Figure 3B).
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3.4. Cytokine and Chemokine Levels in Whole Blood Stimulation by Multiplex ELISA 
In addition to flow cytometric analysis, multiplex ELISA was performed on supernatants to 
evaluate secreted cytokines and chemokines following whole blood stimulation using SUDV. 
During this assay, PHA-L (Phytohaemagglutinin Leukocytes) stimulation was used as a positive 
control for immune cell responses, and unstimulated samples served as baseline controls. The 
unstimulated control results demonstrated that SUDV survivors exhibited equivalent baseline levels 
of cytokines production compared to healthy, uninfected control patients, and PHA-L stimulation 
resulted in equally robust cytokine expression in all patient groups. 
Whole blood stimulation results with irradiated SUDV elicited significantly elevated secretion 
of IL-2, IFNγ, IP-10 and MCP-2 in Ab+/Neut+ survivors, relative to unstimulated, resting cultures 
(Figure 4A,C,F,G). IFNγ, IP-10 and MCP-2 secretion levels in Ab+/Neut+ survivors were also 
significantly increased relative to the other survivor groups tested. SUDV stimulation demonstrated 
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Figure 3. Memory subset analysis of CD4 T cell cytokine responses from survivors and non-infected
controls following SUDV whole antigen stimulation. Subsets of CD4 T cell cytokine responses identified
in Figure 3 were analyzed. (A) CK62L and CD45RO were used to identify TCM (CN45RO+ CD62L+),
TEM (CD45RO+ CD62L´), naïve (CD45RO´ CD62L+), and TEMRA (CD45RO´ CD62L´) T cell subsets.
Each cytokine-producing cell population was overlaid upon the parent CD4 T cell population and
color-coded to identify the expression pattern of CD45RO and CD62L; (B) sCD62l was measured in
supernatants of whole blood resting cultures as well as with SUDV whole antigen. SP: single positive.
3.4. Cytokine and Chemokine Levels in Whole Blood Stimulation by Multiplex ELISA
In addition to flow cytometric analysis, multiplex ELISA was performed on supernatants
to evaluate secreted cytokines and chemokines following whole blood stimulation using SUDV.
During this assay, PHA-L (Phytohaemagglutinin Leukocytes) stimulation was used as a positive control
for immune cell responses, and unstimulated samples served as baseline controls. The unstimulated
control results demonstrated that SUDV survivors exhibited equivalent baseline levels of cytokines
production compared to healthy, uninfected control patients, and PHA-L stimulation resulted in
equally robust cytokine expression in all patient groups.
Whole blood stimulation results with irradiated SUDV elicited significantly elevated secretion of
IL-2, IFNγ, IP-10 and MCP-2 in Ab+/Neut+ survivors, relative to unstimulated, resting cultures
(Figure 4A,C,F,G). IFNγ, IP-10 and MCP-2 secretion levels in Ab+/Neut+ survivors were also
significantly increased relative to the other survivor groups tested. SUDV stimulation demonstrated
no significant increase in secretion levels of IL-5, TNFα, GROα and Eotaxin. Multiplex ELISA results
of IL-1β, IL-4, IL-6, IL-10, IL-17, IL-23, I-309, and MCP-1 showed no differences of cytokine levels
or detectable cytokine signals in survivors and control groups. Further analysis between percent
neutralization (at 1:80 dilution) and cytokine and chemokine secretion levels following stimulation
revealed significant correlation to IL-2 (p = 0.0378), IFNγ (p = 0.0011), IP-10 (p = 0.0006), and MCP-2
(p = 0.0008) expression (Table 2). The complete multiplex ELISA results for the individual survivors
and uninfected controls are presented in Table 3.
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Table 3. Summary of cytokines and chemokines secretion levels by multiplex ELISA following SUDV
whole antigen stimulation in SUDV survivors and non-infected controls.
Cytokine Secretion Chemokine Secretion
IL-2 IL-5 IFNγ TNFα GROα IP-10 MCP-2 Eotaxin
C1 ´ ´ ´ ´ ´ ´ ++ ´
C2 ´ ´ ´ ´ ´ ´ ´ ´
C3 ´ ´ ´ ´ ´ ´ ´ ´
C4 ´ ´ ´ ´ ´ ´ ´ ´
C5 ´ ´ ´ ´ ´ ´ ´ ´
S1 ++ ´ ++ ´ ´ ++ ++ +
S2 ´ ´ ´ ´ ´ ´ ´ ´
S3 ´ ´ ´ ´ ´ ´ ´ ´
S4 + ´ ´ ´ ´ ´ + ´
S5 + ++ ´ ´ ´ ´ ´ ´
S6 ´ ´ ´ ´ ´ ´ ´ ´
S7 + ++ ´ +++ + ´ ´ ´
S8 +++ + + +++ ´ ´ + ´
S9 + ´ ´ ´ ´ ´ + ´
S10 + ´ + ´ ´ + ++ ´
S11 + ´ +++ ´ ´ + ++ ´
S12 +++ ´ +++ ´ ´ + + ´
S13 ++ ´ +++ ´ ´ ++ +++ ++
S14 ++ ´ ++ +++ ´ +++ +++ ´
S15 + ´ ND ´ + ++ +++ ´
S: Ebola survivors, C: non–infected controls, ND: not determined, IL: interleukin, IFN: interferon, TNF: tumor
necrosis factors, IP: IFNγ inducible protein, MCP: monocyte chemotactic protein. (´) = ď cut-off value,
(+) = <2ˆ cut off value, (++) = >2ˆ cut off value and < 4ˆ cut off value, (+++) = >4ˆ cut off value.
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4. Discussion
Ebolavirus causes a severe hemorrhagic fever in humans resulting in a progressive and
overwhelming disease [24]. Various studies support the notion that a robust, specific and adaptive
immune response is required for survival from ebolavirus infection in humans [5,15,25]. These studies
also suggest that protection from ebolavirus requires a balanced immune response with respect to both
humoral and cell mediated immunity [3]. However the interplay between these immune components
in long recovered ebolavirus survivors has not been fully characterized [4].
In this study, we demonstrated that 12-year post infection SUDV survivors present several
distinctive profiles of immunity. Upon SUDV stimulation, significant differences in cytokine and
chemokine expression levels and profiles were observed. A potentially important relationship between
CD4 T cell cytokine expression and neutralizing humoral immunity was observed. Cytokines and
chemokines, such as IL-2, IFNγ, TNFα, IP-10 and MCP-2, which are associated with CD4 T cell
responses, and therefore indicative of T cell memory immunity, were significantly elevated in
individual SUDV survivors with SUDV neutralizing serum activity. In contrast, no correlation was
observed between CD4 T cell responses and the presence of non-neutralizing antibodies in survivors.
Although this is yet to be proven, our thought is that one could make the hypothesis that the increased
CD4 T cell population observed 12 years following the challenge could be indicative of a high viral
load during infection driving a robust T helper response in these individuals. This could lead to
enhanced class switch and affinity maturation to a more “potent” neutralizing phenotype of the
antibody response. Alternatively, the long lasting CD4 T cell response and “potent” neutralizing
response could also be a product of re-exposure to the same or “mimic” antigens that continue to
mature the response. This could be due to the virus remaining in certain immune-privileged sites
in the body as recently seen in the current West Africa outbreak [26], which may have been under
appreciated in previous outbreaks.
The results described herein are in line with previous studies demonstrating that some
long-recovered SUDV survivors can maintain persistent and strong IgG humoral immunity against
SUDV, whereas others demonstrate a complete lack of memory immunity [14,16]. CD8 T cell responses
were rare and may be due to a naturally small cell population or may be attributable to our use of whole
antigens for stimulation. Alternatively, the lack of CD8 T cell responses may be observed due to the
fact that the time point we analyzed is very distant from the survivor's infection. CD8 T cell responses
were demonstrated recently in lymphocytes from EBOV survivors only months after infection using
peptide stimulation [5]. Therefore, we plan to examine if CD8 T cell responses can be detected in these
same SUDV survivors as well with SUDV specific peptide stimulation; however, this is beyond the
scope of the current study.
Multiplex ELISA results following irradiated SUDV stimulation corresponded with flow
cytometry data in that the survivor subgroup with serum neutralizing activity produced the greatest
IFNγ response. In contrast to IFNγ secretion, the TNFα response demonstrated lower secretion levels.
TNFα expression was more broadly detected among all survivors (Figure 4) and was not limited to
the survivor group with serum neutralizing activity, as demonstrated by flow cytometry (Figure 2).
It is unlikely that this difference is attributable to TNFα expression by CD8 T cells as the magnitude
and breadth of CD8 T cell responses was low (supplemental Figure S1). Therefore, it is likely that the
secreted TNFα detected by multiplex ELISA must come from a source other than T cells, although
further evaluation is needed to validate this hypothesis. Further analysis of chemokine expression
demonstrated a significant increase in levels of chemokines IP-10 and MCP-2 in SUDV survivors
with serum neutralizing activity. Although the secretion of those chemokines can be attributed to
various cell types [27], the elevated levels of IP-10 and MCP-2, which are known to play a role in
chemotaxis and activation of T cells during viral infection [28], further support the presence of specific
CD4 memory T cells in the subgroup of SUDV survivors with serum neutralizing activity.
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5. Conclusions
Long-lived humoral immune responses have been characterized previously, but, to our
knowledge, this is the first report detailing ebolavirus-specific CD4 T cell responses in long recovered
human survivors. The results of our study indicate that long-lasting Sudan virus-specific CD4 T helper
cells persist years after recovery in some survivors and, importantly, this phenotype may also correlate
with serum neutralizing activity.
The data presented herein between long-lived cytokine, chemokine and humoral neutralization
responses agrees with the notion that vaccines seeking to confer protection against filovirus exposure
might benefit from eliciting both T cell and neutralizing antibody responses to provide complete and
long-lived immunity. We do not know whether or not any of the survivors in this study may have
had T cell responses that attenuated in the years since the outbreak. Nonetheless, our data in this
specific cohort indicates that CD4 T cell responses and neutralizing antibody titers were linked in
SUDV survivors in this window of time, even a decade post infection. What remains to be seen is
if the relationship observed in this subset of patients, and in this particular cohort at this particular
time point, is recapitulated in other survivor cohorts at varying time points following viral clearance.
However, the study does make clear that clinical correlates and long term memory immune responses
need to be further investigated in larger prospective human cohort studies of filovirus vaccine and
therapeutic treatment modalities.
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